Generic User Fees Would Create 10-Month ANDA Review Time
This article was originally published in The Pink Sheet Daily
Executive Summary
Annual revenue of $250 million to $300 million in generic drug user fees is discussed as FDA unveils its "four walls and a roof" guiding principles.
You may also be interested in...
US FDA's Generics Program Reaches 'Steady State' Milestone
OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.
US FDA's Generics Program Reaches 'Steady State' Milestone
OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.
FDA Drug Review Costs Rise, But Personnel Spending Flattens
Less than 60% of the total spending on reviews was attributed to employee compensation and benefits in FY 2011. FDA says it is normal, but the figure is lower than costs seen in recent years.